Actavis may begin selling limited quantities of a generic, abuse-resistant form of Purdue Pharma's opioid painkiller OxyContin on Jan. 1, 2014, under a deal reached by the two drugmakers. If the FDA does not approve Actavis' generic version, the deal allows the company to sell an authorized generic.

Full Story:
Drug Store News

Related Summaries